Form 4: Zeo ScientifiX Director Charles Luther Bretz Reports Stock Option Grant

Director Charles Luther Bretz reports the acquisition of stock options in Zeo ScientifiX, Inc.

Summary

• Charles Luther Bretz, a director of Zeo ScientifiX, Inc. (ZEOX), reported a transaction on April 1, 2024.
• Bretz acquired 5,000 stock options with an exercise price of $2.
• 2,500 of these options vested immediately on April 1, 2024, and the remaining 2,500 will vest on September 23, 2024.
• The options expire on April 1, 2029.
• Following the reported transaction, Bretz directly owns 5,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants. The vesting schedule is fairly standard.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the technology and biotechnology industries, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies.
• The size and vesting schedule of the grant would need to be compared to similar companies in the same industry to determine if it is within the typical range.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use stock options as part of their compensation strategy.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates